Tocagen’s brain tumour candidate gets PRIME designationAn early-stage drug candidate for hard-to-treat brain tumours has been granted special ‘PRIME’ status by the European Medicines Share XTocagen’s brain tumour candidate gets PRIME designationhttps://pharmaphorum.com/news/tocagens-brain-tumour-treatment-gets-prime-designation/
Immunotherapy for brain cancer gets European PRIME statusLatest addition to EMA’s fast-track for cutting edge drugs Share XImmunotherapy for brain cancer gets European PRIME statushttps://pharmaphorum.com/news/immunotherapy-brain-cancer-gets-european-prime-status/
Europe launches new PRIME fast-track for promising medicinesAndrew McConaghie reports on a newly-launched plan to speed up access to groundbreaking new medicines in Europe. Share XEurope launches new PRIME fast-track for promising medicineshttps://pharmaphorum.com/articles/europe-launches-new-prime-fast-track-for-promising-medicines/